These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38329919)

  • 1. Gastric Burkitt's monomorphic post-transplant lymphoproliferative disorder after kidney transplantation: A case report.
    Yoshimura Y; Suwabe T; Fujiki A; Kaji D; Asano-Mori Y; Oba Y; Mizuno H; Yamanouchi M; Tanaka K; Hasegawa E; Miki K; Yokoyama T; Namamura Y; Ishii Y; Yamashita S; Kono K; Kinowaki K; Takazawa Y; Sawa N; Ubara Y
    Clin Nephrol; 2024 May; 101(5):250-256. PubMed ID: 38329919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T; Kawano N; Yamashita K; Ueda A
    J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term remission in an adult heart transplant recipient with advanced Burkitt's lymphoma post-transplant lymphoproliferative disorder after anthracycline-free chemotherapy: A case report and literature review.
    AbdelHameid D; Felice A; Cooper LB; Katugaha SB
    Transpl Infect Dis; 2020 Aug; 22(4):e13265. PubMed ID: 32077552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
    Ashoor IF; Al-Akash S; Kizilbash S; Moudgil A; Puliyanda D; Ranabothu S; Shi Y; Dharnidharka V
    Pediatr Transplant; 2024 May; 28(3):e14743. PubMed ID: 38566336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma.
    Lohrisch CA; Nevill TJ; Barnett MJ; Hogge DE; Connors JM; Keown PA; Gascoyne RD
    Leuk Lymphoma; 2000 Sep; 39(1-2):195-201. PubMed ID: 10975399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type.
    Ergisi M; Ooi B; Salim O; Papalois V
    Transplant Rev (Orlando); 2024 Apr; 38(2):100837. PubMed ID: 38430887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
    Dutta R; Miao SY; Phan P; Fernandez-Pol S; Shiraz P; Ho D; Mannis GN; Zhang TY
    J Med Case Rep; 2021 Mar; 15(1):170. PubMed ID: 33773605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spleen-Restricted Posttransplant Lymphoproliferative Disorder in the First Year After Kidney Transplant - A Case Report.
    Rodrigues AC; Fernandes S; Bustorff M; Nunes AT; Ferreira I; Tavares I; Rocha A; Carneiro A; Sampaio SN
    Transplant Proc; 2022; 54(6):1624-1626. PubMed ID: 35487782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys.
    Schmidtko J; Wang R; Wu CL; Mauiyyedi S; Harris NL; Della Pelle P; Brousaides N; Zagachin L; Ferry JA; Wang F; Kawai T; Sachs DH; Cosimi BA; Colvin RB
    Transplantation; 2002 May; 73(9):1431-9. PubMed ID: 12023621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
    Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.